Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF
Cascio, A., Colomba, C., Di Rosa, D., Salsa, L., di Martino, L., & TITONE LANZA DI SCALEA, L. (2001). Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. CLINICAL INFECTIOUS DISEASES, 33(3), 409-411.
Data di pubblicazione: | 2001 |
Titolo: | Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial |
Autori: | |
Citazione: | Cascio, A., Colomba, C., Di Rosa, D., Salsa, L., di Martino, L., & TITONE LANZA DI SCALEA, L. (2001). Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. CLINICAL INFECTIOUS DISEASES, 33(3), 409-411. |
Rivista: | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Efficacy and Safety of Clarithromycin.pdf | N/A | Open Access Visualizza/Apri |